Figure 4
Figure 4. Effect of PKC inhibition on CLL cell survival. CLL cells were treated with the indicated inhibitors and measured for viability. Viability of the treated cells was normalized to that of untreated cells and is reported as a percentage thereof. (A) Viability (mean ± SD) of CLL cells incubated with 1 μM LY379196 for 5 days (n = 15). (B) Viability of CLL cells incubated with 10 μM Ro32-0432 for 3 days (n = 4). Tests for statistical significance were performed using Student t test for paired data. (C) pS180-Btk was immunoprecipitated from RIPA lysates of CLL cells incubated in the presence or absence of 100 nM LY379196. Immunoprecipitated proteins and whole cell lysates were separated by SDS-PAGE, and Western blots were probed with anti-Btk antibodies. CLL A, CLL B, and CLL C are new patients not represented in Table S1.

Effect of PKC inhibition on CLL cell survival. CLL cells were treated with the indicated inhibitors and measured for viability. Viability of the treated cells was normalized to that of untreated cells and is reported as a percentage thereof. (A) Viability (mean ± SD) of CLL cells incubated with 1 μM LY379196 for 5 days (n = 15). (B) Viability of CLL cells incubated with 10 μM Ro32-0432 for 3 days (n = 4). Tests for statistical significance were performed using Student t test for paired data. (C) pS180-Btk was immunoprecipitated from RIPA lysates of CLL cells incubated in the presence or absence of 100 nM LY379196. Immunoprecipitated proteins and whole cell lysates were separated by SDS-PAGE, and Western blots were probed with anti-Btk antibodies. CLL A, CLL B, and CLL C are new patients not represented in Table S1.

Close Modal

or Create an Account

Close Modal
Close Modal